A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

Tokyo, Aug. 6 (Jiji Press)--A Japanese health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an ...

Eli Lilly & Biogen's Alzheimer's drugs may offer minimal impact despite aggressive marketing. Click here to get insights on ...

Eisai unveiled much-anticipated findings on its experimental Alzheimer’s drug, providing tinder for the hot debate over whether its modest efficacy is worth potential risks that include serious ...

TOKYO -- Japanese drugmaker Eisai said Wednesday it will invest up to $15 million in C2N Diagnostics, a U.S. biotechnology firm that has developed a blood test for early signs of Alzheimer's disease.

Eisai intends for the drug to be injected into fleshy parts of the body, such as the stomach or thighs. The number of injections and doses are still under consideration.

SAN FRANCISCO--An experimental Alzheimer’s disease drug from Eisai and Biogen slowed cognitive decline in a closely watched trial but may carry a risk of dangerous side effects for certain ...

TOKYO, May 23, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) ...

TOKYO, March 4 (Reuters) - Eisai Co <4523.T>, Japan's No.4 drugmaker, said it expects annual U.S. sales of its flagship Alzheimer's drug Aricept to fall 60 percent in three years, hit by the ...

Review the current Eisai Co Ltd (4523:XTKS) dividend yield and history to decide if 4523 is the best investment for you.

Eisai Thailand submitted an application for marketing authorization in Thailand in March 2023, and received approval in June 2024. This launch is the first within Eisai's licensed region.